Narayana Health buys UK's Practice Plus Hospitals

Bengaluru's Narayana Health is making waves in the UK healthcare landscape with its acquisition of Practice Plus Group Hospitals, which manages 12 facilities. This strategic move is all about delivering affordable healthcare options to a broader audience.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/uJTX7bp
via IFTTT

Read More

Narayana Health acquires UK’s Practice Plus Group Hospitals in Rs 2,200 crore deal

Narayana Hrudayalaya Ltd has acquired UK's Practice Plus Group Hospitals for approximately Rs 2,200 crore. This strategic move marks Narayana Health's entry into the UK healthcare market. The acquisition includes seven hospitals and several other facilities. Dr Devi Shetty stated the deal aims to make private healthcare more accessible and affordable.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/mZigRxT
via IFTTT

Read More

US biosimilar norms to keep local drug cos in good health

With the new regulations set by the US FDA, the pathway to creating biosimilars will be both faster and more cost-effective. This development is a game changer for Indian firms like Biocon and Dr Reddy's Laboratories, allowing them to provide more economical medicines to patients.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/FT7B2hj
via IFTTT

Read More

Made in India new generation heart stent receives major global recognition

An Indian-made heart stent, Supraflex Cruz, has demonstrated a lower failure rate in high-risk patients compared to a US-made market leader. The TUXEDO-2 trial, conducted in India, showed the Indian stent to be non-inferior and resulted in significantly lower Target Lesion Failures, including cardiac death and heart attacks.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/aiTWQR7
via IFTTT

Read More

Cipla plans 4 major respiratory launches by 2026 after beating Q2 estimates with highest-ever quarterly revenue of Rs 7,500+ cr

Cipla Ltd reported a record second-quarter revenue exceeding Rs 7,500 crore, driven by strong demand for its respiratory drugs and a growing chronic portfolio. The company maintained its second position in India's chronic market and saw significant progress in its U.S. respiratory and biosimilar segments, with four major respiratory assets slated for launch by 2026.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/vJO7TED
via IFTTT

Read More

Zero GST on health insurance plans sparks 38% surge in demand: Report

Health insurance demand has surged by 38 percent following the removal of GST. Individuals are now opting for higher coverage amounts, with the average sum insured increasing significantly. This trend is observed across various age groups and even in smaller cities. The exemption makes health and life insurance more affordable, encouraging comprehensive protection against rising healthcare costs.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/PJdcy73
via IFTTT

Read More

Drug cos forging data for approval, mislabelling brands to be barred

In a bold move to combat deception in the pharmaceutical industry, the government is instituting strict penalties for drugmakers caught submitting forged or misleading documents during the approval process. This initiative is a direct response to the tragic incidents of child fatalities linked to tainted cough syrups.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/4ltOwLk
via IFTTT

Read More